TriangleHEALTH PROFESSIONAL · SOURCE READING
Asciminib
Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 13, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Relapsed CML / Treatment Options for Relapsed CML / Targeted therapy with TKIs
Asciminib is an allosteric inhibitor of BCR::ABL1 at the ABL1 myristoyl pocket, a site unique from those used by TKIs.
Evidence (asciminib):
An open-label randomized clinical trial compared asciminib with bosutinib. With a median follow-up of 14.9 months, 233 patients with refractory or resistant disease were randomly assigned in a 2:1 ratio to receive either asciminib or bosutinib.[23]
Source links and citations
An open-label randomized clinical trial compared asciminib with bosutinib. With a median follow-up of 14.9 months, 233 patients with refractory or resistant disease were randomly assigned in a 2:1 ratio to receive either asciminib or bosutinib.[23]
The major molecular response (MMR) rate at week 24 was 25.5% for patients who received asciminib versus 13.2% for patients who received bosutinib. The difference in response (adjusted for major cytogenetic response at baseline) was 12.2% (95% CI, 2.19%–22.30%; P = .029).[23][Level of evidence B3]
Source links and citations
An open-label randomized clinical trial compared asciminib with bosutinib. With a median follow-up of 14.9 months, 233 patients with refractory or resistant disease were randomly assigned in a 2:1 ratio to receive either asciminib or bosutinib.[23]
Grade 3 or 4 adverse events were experienced by 50.6% of patients who received asciminib and 60.5% of patients who received bosutinib.
A phase I trial of asciminib included heavily pretreated patients who experienced resistance or unacceptable side effects after standard TKIs. Patients with a T315I variant and those in whom ponatinib failed were included.[24][Level of evidence C3]
Source links and citations
A phase I trial of asciminib included heavily pretreated patients who experienced resistance or unacceptable side effects after standard TKIs. Patients with a T315I variant and those in whom ponatinib failed were included.[24][Level of evidence C3]
Of 141 patients, 48% achieved an MMR by 12 months.
A phase II trial included 31 patients who received asciminib.[25][Level of evidence C3]
Source links and citations
A phase II trial included 31 patients who received asciminib.[25][Level of evidence C3]
An MMR rate of 41% was reported by 12 months.
A phase II trial included 31 patients who received asciminib.[25][Level of evidence C3]
Three of nine patients with disease that failed to respond to previous ponatinib responded to asciminib.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice